trending Market Intelligence /marketintelligence/en/news-insights/trending/jU27Qo0Ni_OTk7i6lsTBqQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Amgen, China's BeiGene close $2.8B cancer partnership deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Amgen, China's BeiGene close $2.8B cancer partnership deal

Amgen Inc. and China's BeiGene Ltd. completed their $2.8 billion collaboration deal after meeting the closing conditions of the agreement.

Under the cancer partnership, Amgen acquired a 20.5% stake in BeiGene by purchasing 15,895,001 American depositary shares at $174.85 each.

As part of the collaboration, BeiGene will be responsible for the commercialization of Amgen cancer drugs Xgeva, Kyprolis and Blincyto in the Chinese market.

The companies will also work together in research and development for 20 new drugs in Amgen's pipeline, and BeiGene will contribute up to $1.25 billion to that effort. For that, the Chinese company will hold the commercial rights to any drugs that get the country's approval.

BeiGene also said former Amgen executive vice president of global commercial operations Anthony Hooper was added to the company's board as part of the share sale.